Literature DB >> 28364450

Detecting the Cognitive Prodrome of Dementia with Lewy Bodies: A Prospective Study of REM Sleep Behavior Disorder.

Daphné Génier Marchand1,2, Jacques Montplaisir2,3, Ronald B Postuma2,4, Shady Rahayel1,2, Jean-François Gagnon1,2.   

Abstract

Study
Objectives: Long-term studies in REM sleep behavior disorder (RBD) have shown a high rate of conversion into synucleinopathies. We aimed to prospectively follow-up a large cohort of RBD patients to identify cognitive markers for early detection of prodromal dementia.
Methods: Seventy-six idiopathic RBD patients underwent polysomnography and a complete neuropsychological and neurological assessment and were then followed for a mean of 3.6 years. Cognitive characteristics at baseline were compared between patients who remained disease-free and those who developed a synucleinopathy, and between those who developed dementia first and those who developed parkinsonism first. Receiver operating characteristic curves were calculated to assess the diagnostic value of cognitive tests for detecting prodromal dementia.
Results: At follow-up, 34 patients developed a neurodegenerative disease: 19 parkinsonism-first and 15 dementia-first. RBD patients who first developed dementia were impaired at baseline in all cognitive domains (attention/executive functions, learning/memory, and visuospatial) compared to patients who developed parkinsonism. Moreover, 93% of patients who first developed dementia had mild cognitive impairment at baseline compared to 42% of patients who developed parkinsonism. RBD patients who developed parkinsonism first were similar at baseline to disease-free RBD patients on cognition. In dementia-first patients, two cognitive tests assessing attention and executive functions (Stroop Color Word Test and Trail Making Test) reliably predicted dementia (area under the curve ≥0.85) compared to parkinsonism-first patients or controls. Conclusions: This study shows that cognitive tests assessing attention and executive functions strongly predict conversion to dementia in RBD patients, and may be useful endpoints to determine the effectiveness of interventions to prevent cognitive deterioration in RBD patients. © Sleep Research Society 2016. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Parkinson’s disease; REM sleep behavior disorder; cognition; dementia with Lewy bodies; neuropsychological assessment.

Mesh:

Year:  2017        PMID: 28364450     DOI: 10.1093/sleep/zsw014

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  22 in total

Review 1.  Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies.

Authors:  Daniel A Barone; Claire Henchcliffe
Journal:  Clin Neurophysiol       Date:  2018-05-29       Impact factor: 3.708

Review 2.  Idiopathic REM sleep behaviour disorder and neurodegeneration - an update.

Authors:  Birgit Högl; Ambra Stefani; Aleksandar Videnovic
Journal:  Nat Rev Neurol       Date:  2017-11-24       Impact factor: 42.937

3.  Cortical and subcortical gray matter bases of cognitive deficits in REM sleep behavior disorder.

Authors:  Shady Rahayel; Ronald B Postuma; Jacques Montplaisir; Daphné Génier Marchand; Frédérique Escudier; Malo Gaubert; Pierre-Alexandre Bourgouin; Julie Carrier; Oury Monchi; Sven Joubert; Frédéric Blanc; Jean-François Gagnon
Journal:  Neurology       Date:  2018-04-18       Impact factor: 9.910

Review 4.  The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

Authors:  Daniel Weintraub; Eugenia Mamikonyan
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-09       Impact factor: 4.105

5.  Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder.

Authors:  Eun Jin Yoon; Jee-Young Lee; Heejung Kim; Dallah Yoo; Jung Hwan Shin; Hyunwoo Nam; Beomseok Jeon; Yu Kyeong Kim
Journal:  Neurology       Date:  2022-04-18       Impact factor: 11.800

Review 6.  Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinson's Disease and Other Synucleinopathies.

Authors:  Matej Skorvanek; Eva Feketeova; Monica M Kurtis; Jan Rusz; Karel Sonka
Journal:  Front Neurol       Date:  2018-05-25       Impact factor: 4.003

Review 7.  Relationships between Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: Clinical Assessments, Biomarkers, and Treatment.

Authors:  Min Li; Li Wang; Jiang-Hong Liu; Shu-Qin Zhan
Journal:  Chin Med J (Engl)       Date:  2018-04-20       Impact factor: 2.628

Review 8.  Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.

Authors:  Mitchell G Miglis; Charles H Adler; Elena Antelmi; Dario Arnaldi; Luca Baldelli; Bradley F Boeve; Matteo Cesari; Irene Dall'Antonia; Nico J Diederich; Kathrin Doppler; Petr Dušek; Raffaele Ferri; Jean-François Gagnon; Ziv Gan-Or; Wiebke Hermann; Birgit Högl; Michele T Hu; Alex Iranzo; Annette Janzen; Anastasia Kuzkina; Jee-Young Lee; Klaus L Leenders; Simon J G Lewis; Claudio Liguori; Jun Liu; Christine Lo; Kaylena A Ehgoetz Martens; Jiri Nepozitek; Giuseppe Plazzi; Federica Provini; Monica Puligheddu; Michal Rolinski; Jan Rusz; Ambra Stefani; Rebekah L S Summers; Dallah Yoo; Jennifer Zitser; Wolfgang H Oertel
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 44.182

9.  Insomnia symptom subtypes and manifestations of prodromal neurodegeneration: a population-based study in the Canadian Longitudinal Study on Aging.

Authors:  Chun W Yao; Amélie Pelletier; Seyed-Mohammad Fereshtehnejad; Nathan Cross; Thanh Dang-Vu; Ronald B Postuma
Journal:  J Clin Sleep Med       Date:  2022-02-01       Impact factor: 4.062

10.  Apathy in rapid eye movement sleep behaviour disorder is common and under-recognized.

Authors:  T R Barber; K Muhammed; D Drew; M Lawton; M Crabbe; M Rolinski; T Quinnell; Z Zaiwalla; Y Ben-Shlomo; M Husain; M T M Hu
Journal:  Eur J Neurol       Date:  2017-12-14       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.